Well as we approach 2022 Years End thought it best to kick start...

Well as we approach 2022 Years End thought it best to kick start a new thread for the upcoming Pivotal Year Ahead.....

MND Motor Neuron Disease , Fully Funded by MND Australia

6 Trial Patients are already underway with 1 completing the first month of the escalating dose format.
The remaining 5 would have completed their first month by the 11th of December.
With no adverse effects or Tolerability issues which is a huge leap forward from the original capsules 7 years ago.

K9 Cancer
K9 Phase II Transitioning to a Phase III , specialist negotiator brought on board to secure a Phase III K9 Lymphoma Trial Partner or early Commercial Deal.
The Company already has solid confirmation of the benefits of MPL and now wish to trial with a companion drug to increase the benefits to K9's , this data will be utilised for the upcoming Human Lymphoma Trials.

The Company has been in extended discussions now for 3 years with Big Pharma hoping to ink a commercial partner.
Many Trial Patient Trial K9 owners testimonials are on the Company website..

Human Oncology
Human Oncology , PAA intend to replicate the Positive Results from the 2016 Human Cancer Trial negating any of the previous minor adverse effects. This will be a "Take at Home" cancer treatment with no harmful adverse side effects negating the use of aggressive Chemotherapy.

The K9 cancer data gathered will integral and highly beneficial moving forward through 2023.

HVTL-1 , Leukemia
HVTL-1 Based Virus the cousin of HIV and a precursor to Leukemia ,WEHI identified Positive effect of MPL.
WEHI have triple tested MPL vs Leukemia in February 2022
>WEHI shows MPL and MPLS kill HTLV-1 transformed leukaemia cell lines
● WEHI shows MPL and MPLS inhibit HTLV-1 protein production
● Further investigations required to understand mechanism and clinical significance

This Human data adds to the already extensive data gathered by the Olivia Newton John Foundation data which tested MPL against 30 Human cancers and demonstrated beneficial results across 28 Human Cancers with In Vitro testing..


MPL GMP Grade Tablets Completed
The company has taken delivery of the refined and micronised MPL , "Pharmapantel" the Tablets/Pill has been designed to be very small to reduce patient burden and easier to swallow.
Tablet Manufacture was completed in April 2022 with the Global assistance of Catalent USA and Sygene India, the collaborative effort brings only the 3rd mTOR pathway drug to date , The other 2 Companies Pfizer and Novartis share a market valued at $2.4B
Pharmaust to date has had no adverse effects from the newly formulated tablets , this delivers a huge commercial advantage above and beyond the current market incumbents.

OHD Reactor
During the year Pharmaust has entered into a trial partnership with Shell Oil
A scalable Test plant is being constructed in partnership to enable a Real World proof of concept facility that Pharmaust hope to build on moving forward through out 2023//

OHD Bench top Reactor pictured at Epichem


Epichem


Epichem is a 100% owned stand alone Research Facility owned by Pharmaust
Epichem employs 18 PHD's and has won Western Australia Medical Export awards for the past 7 years.
Epichem is the most advanced laboratory in Perth meeting and in most cases exceeding Global Industry Standards..


2023 is Pharmausts year in the Spotlight , NZT